Data assessing the effectiveness of intracavernosal injections (ICIs) for the treatment of erectile dysfunction (ED) are limited. This study evaluates intracavernosal injectable therapies for ED and reviews available guidelines that inform clinical practice.
A systematic search using electronic databases (Medline, Pubmed) was performed for studies investigating injectable management strategies for ED published after 1990. Primary outcome measures were to comparatively evaluate clinical efficacy, continuation rates and adverse event profiles of each injectable agent as monotherapy or in combination. The secondary outcome measurement was to discuss available guidelines that inform clinical practice for injectable agents.
ICIs demonstrate clinical efficacy in 54–100% of patients, early discontinuation rates of ≤ 38% and adverse events in ≤ 26%. Discontinuation rates are typically greatest within 3–6 months of commencement. Anxiety related to the initial injection occurs in approximately 65% and anxiety levels can remain high for 4 months. Approval of intracavernosal injection agents is mainly limited to alprostadil with the recent addition of aviptadil/phentolamine combination therapy in a select few geographical regions. Although combination therapies are attractive alternative options, their formulations are variable and should be standardised before widespread acceptance is achieved.
ICIs are associated with good clinical efficacy rates, high discontinuation rates and a moderate side-effect profile. They represent an important tool in the urological armamentarium for treating ED in patients that cannot tolerate or are refractory to oral therapies.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
American Urology Association
British Society of Sexual Medicine
Cyclic adenosine monophosphate
Cyclic guanosine monophosphate
European Association of Urology
Food and Drug Authority, USA
Japanese Society of Sexual Medicine
Korean Society of Sexual Medicine
Phosphodiesterase type 5
Therapeutic Goods Administration, Australia
Vasoactive intestinal polypeptide
Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS et al (2018) Erectile dysfunction: AUA guideline. J Urol 07:07
Bella AJ, Lee JC, Carrier S, Benard F, Brock GB (2015) 2015 CUA Practice guidelines for erectile dysfunction. Can Urol Assoc J 9(1–2):23–29
Hatzimouratidis K, Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A et al (2010) Pharmacotherapy for erectile dysfunction: recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med 13(4):465–488
Linet OO, Ogrinc FG, for the Alprostadil Study Group (1996) Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 334(14):873–877
Rabbani KJ, Tauqeer F, Rabbani R (2010) Prostaglandin E1 for the medical management of erectile dysfunction. Pak J Med Health Sci 4(4):515–519
Khan MM, Khwaja M (2005) Open label study of intracavernous injection of alpostadil alphadex in the treatment of erectile dysfunction. J Postgrad Med Inst 19(1):52–57
Virag RF, Frydman D, Legman M, Virag H (1984) Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 35(2):79–87
Dinsmore WW, Wyllie MG (2008) Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int 102(8):933–937
Sogari PR, Teloken C, Souto CA (1997) Atropine role in the pharmacological erection test: study of 228 patients. J Urol. 158(5):1760–1763
Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP (2012) A review of outcomes of an intracavernosal injection therapy programme. BJU Int 110(11):1787–1791
Aulitzky A, Bazarnik J, Kiper J, Bolyakov A, Paduch D (2012) Safety and efficacy of intracavernosal injection therapy with concomitant daily or as needed tadalafil in men with postprostatectomy and severe erectile dysfunction. J Sex Med 1:54
Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J et al (2016) EAU guidelines on erectile dysfunction: an update. Eur Urol 49(5):806–815
Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M et al (2017) British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 5(8):1841–1865
Ryu JK, Cho KS, Kim SJ, Oh KJ, Kam SC, Seo KK et al (2013) Korean Society for Sexual Medicine and Andrology (KSSMA) guideline on erectile dysfunction. World J Mens Health 31(2):83–102
Nelson CJ, Hsiao W, Balk E, Narus J, Tal R, Bennett NE et al (2013) Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J Sex Med 10(10):2559–2565
Andrology Australia (2010) Erectile dysfunction: diagnosis and management. https://www.andrologyaustralia.org/wp-content/uploads/clinical-summary-guide09_May20101.pdf
Capogrosso P, Montorsi F, Salonia A (2018) Phase I and phase II clinical trials for the treatment of male sexual dysfunction—a systematic review of the literature. Expert Opin Investig Drugs 27(7):583–593
O’Kane D, Gibson L, Du Plessis J, Davidson A, Bolton D, Lawrentschuk N (2017) Delivery of intracavernosal therapies using needle-free injection devices. Int J Impot Res 29(6):225–228
Kimoto Y, Nagao K, Sasaki H, Marumo K, Takahashi Y, Nishi S et al (2008) JSSM guidelines for erectile dysfunction. Int J Urol 15(7):564–576
No funding was provided for this review.
Conflict of interest
None of the authors have conflicts of interest to disclose.
Ethics approval for this project was not required as no human or animal participants were involved in this review.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Duncan, C., Omran, G.J., Teh, J. et al. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol 37, 1007–1014 (2019). https://doi.org/10.1007/s00345-019-02727-5
- Erectile dysfunction (ED)
- Intracavernosal injections
- Treatment of erectile dysfunction
- Treatment of ED